var data={"title":"Treatment of pulmonary tuberculosis in HIV-infected adults: Initiation of therapy","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Treatment of pulmonary tuberculosis in HIV-infected adults: Initiation of therapy</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/contributors\" class=\"contributor contributor_credentials\">Timothy R Sterling, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/contributors\" class=\"contributor contributor_credentials\">C Fordham von Reyn, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/contributors\" class=\"contributor contributor_credentials\">Elinor L Baron, MD, DTMH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Mar 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Oct 24, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Initiation of therapy for treatment of drug-susceptible pulmonary tuberculosis (TB) in human immunodeficiency virus (HIV)-infected adults must address potential drug interactions, adverse drug reactions, and optimal timing for initiation of antiretroviral therapy (ART) in ART-na&iuml;ve patients [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/1-5\" class=\"abstract_t\">1-5</a>].</p><p>Issues related to initiation of therapy for treatment of HIV-infected patients with TB are reviewed here. Issues related to follow-up after initiation of therapy are discussed separately. (See <a href=\"topic.htm?path=treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy\" class=\"medical medical_review\">&quot;Treatment of pulmonary tuberculosis in HIV-infected adults: Follow-up after initiation of therapy&quot;</a>.)</p><p>General principles related to antituberculous therapy for treatment of drug-susceptible TB in HIV-uninfected adults are discussed separately. (See <a href=\"topic.htm?path=treatment-of-drug-susceptible-pulmonary-tuberculosis-in-hiv-uninfected-adults\" class=\"medical medical_review\">&quot;Treatment of drug-susceptible pulmonary tuberculosis in HIV-uninfected adults&quot;</a>.)</p><p>The clinical features and diagnosis of TB disease in HIV-infected patients are discussed separately. (See <a href=\"topic.htm?path=diagnosis-of-pulmonary-tuberculosis-in-adults\" class=\"medical medical_review\">&quot;Diagnosis of pulmonary tuberculosis in adults&quot;</a>.)</p><p>Beyond issues related to ART discussed here, general principles related to ART are discussed further separately. (See <a href=\"topic.htm?path=selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient\" class=\"medical medical_review\">&quot;Selecting antiretroviral regimens for the treatment-na&iuml;ve HIV-infected patient&quot;</a> and <a href=\"topic.htm?path=overview-of-antiretroviral-agents-used-to-treat-hiv\" class=\"medical medical_review\">&quot;Overview of antiretroviral agents used to treat HIV&quot;</a>.)</p><p>Issues related to drug-resistant TB are discussed separately. (See <a href=\"topic.htm?path=treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults\" class=\"medical medical_review\">&quot;Treatment of drug-resistant pulmonary tuberculosis in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">GENERAL PRINCIPLES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Management of tuberculosis (TB) in HIV-infected patients should include attention to the following principles:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Infection control &ndash; Issues related to tuberculosis transmission and control are discussed separately (see <a href=\"topic.htm?path=tuberculosis-transmission-and-control\" class=\"medical medical_review\">&quot;Tuberculosis transmission and control&quot;</a>). The principles are the same for HIV-infected patients as they are for HIV-uninfected patients.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Administration of an appropriate regimen for TB &ndash; The antituberculous regimen must be made with close attention to potential drug interactions with antiretroviral agents. The initial regimen is empiric and must be tailored to drug susceptibility results when available. In general, antituberculous regimens consists of two phases: an intensive phase of four drugs administered daily for two months, followed by a continuation phase of two drugs given for four to seven months [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/1\" class=\"abstract_t\">1</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Directly observed therapy (DOT) &ndash; All patients with tuberculosis should be treated with DOT; it is the most effective way to maximize adherence and is recommended by the World Health Organization (WHO) [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/1,6\" class=\"abstract_t\">1,6</a>]. DOT programs are very effective in decreasing rates of primary and acquired drug resistance [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/7,8\" class=\"abstract_t\">7,8</a>]. In countries where TB and HIV are endemic, DOT has been associated with lower TB relapse rates and a higher percentage of patients who complete the full duration of TB therapy [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/9,10\" class=\"abstract_t\">9,10</a>]. (See <a href=\"topic.htm?path=adherence-to-tuberculosis-treatment\" class=\"medical medical_review\">&quot;Adherence to tuberculosis treatment&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Administration of appropriate antiretroviral therapy (ART) for HIV &ndash; Initiation or revision of ART must be made with close attention to the timing of initiation as well as potential drug interactions with TB medications.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Close monitoring for treatment response &ndash; The approach to follow-up after initiation of therapy is discussed separately. (See <a href=\"topic.htm?path=treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy\" class=\"medical medical_review\">&quot;Treatment of pulmonary tuberculosis in HIV-infected adults: Follow-up after initiation of therapy&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Close monitoring for immune reconstitution inflammatory syndrome (IRIS) &ndash; IRIS is a paradoxical worsening of a preexisting infectious process following immune recovery associated with administration of ART. The risk of IRIS appears to depend on the baseline CD4 cell counts (baseline CD4 cell counts &lt;50 <span class=\"nowrap\">cells/microL</span> confers greatest risk) and the timing of ART initiation relative to TB medications. (See <a href=\"#H1059142102\" class=\"local\">'Timing'</a> below and <a href=\"topic.htm?path=treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy#H11\" class=\"medical medical_review\">&quot;Treatment of pulmonary tuberculosis in HIV-infected adults: Follow-up after initiation of therapy&quot;, section on 'Immune reconstitution inflammatory syndrome'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H319082495\"><span class=\"h1\">TB DIAGNOSED PRIOR TO HIV</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with an established diagnosis of tuberculosis (TB) disease warrant prompt initiation of antituberculous therapy as well as human immunodeficiency virus (HIV) testing. Patients with TB who are HIV-infected warrant initiation of antiretroviral therapy (ART) regardless of CD4 count [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/1,2,11\" class=\"abstract_t\">1,2,11</a>]; the approach is discussed in the following sections.</p><p class=\"headingAnchor\" id=\"H3100743462\"><span class=\"h2\">Antituberculous therapy</span></p><p class=\"headingAnchor\" id=\"H563844985\"><span class=\"h3\">Regimen selection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with pulmonary TB should begin antituberculous therapy promptly. An empiric four-drug regimen should be initiated (<a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a>, <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a>, <a href=\"topic.htm?path=pyrazinamide-drug-information\" class=\"drug drug_general\">pyrazinamide</a>, and <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a>) with pyridoxine and daily therapy using directly observed therapy (DOT) until drug susceptibility results are available.</p><p>Depending on the ART regimen chosen subsequently, adjustment of the antituberculous regimen may be required (for example, <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a> may need to be substituted for <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> in some cases).</p><p class=\"headingAnchor\" id=\"H1427539624\"><span class=\"h3\">Dosing interval</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with TB and HIV infection should receive daily antituberculous therapy (five to seven days per week) during the intensive phase (initial two months of treatment) and during the continuation phase (at least four additional months after the intensive phase) (<a href=\"image.htm?imageKey=ID%2F58653\" class=\"graphic graphic_table graphicRef58653 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/1,2\" class=\"abstract_t\">1,2</a>].</p><p>This approach is supported by a meta-analysis in which thrice-weekly therapy in the initial phase was associated with higher rates of treatment failure than daily therapy (adjusted risk ratio 4.0, 95% CI 1.5-10.4) and relapse (adjusted risk ratio 4.8, 95% CI 1.8-12.8) [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/12,13\" class=\"abstract_t\">12,13</a>].</p><p>Patients with TB and HIV infection (particularly those with &lt;100 CD4 <span class=\"nowrap\">lymphocytes/microL)</span> should not be treated with regimens administered once or twice weekly [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/2,14,15\" class=\"abstract_t\">2,14,15</a>]. Among HIV-infected patients with advanced immunosuppression, intermittent TB therapy has been identified as a risk factor for relapse and acquired rifamycin resistance [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/14,16-19\" class=\"abstract_t\">14,16-19</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In one study including 71 HIV-infected patients on TB induction therapy for two months, once-weekly <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a> and <a href=\"topic.htm?path=rifapentine-drug-information\" class=\"drug drug_general\">rifapentine</a> was compared with twice-weekly isoniazid and <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> in the continuation phase of DOT [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/16\" class=\"abstract_t\">16</a>]. Relapse was observed in 13 percent of patients who completed therapy; rifamycin monoresistance was observed at the time of relapse in 80 percent of patients in the once-weekly group compared with none of the patients in the twice-weekly group. Patients who relapsed had lower baseline CD4 cell counts than nonrelapsers (median CD4 count 16 versus <span class=\"nowrap\">144/microL)</span> and were more likely to have extrapulmonary involvement at baseline (75 versus 18 percent).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a single-arm trial including 169 patients treated with twice-weekly <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a> and <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a> in the continuation phase, treatment failure or relapse was observed in 5 percent of cases; of these, acquired rifamycin resistance was observed in 89 percent of patients, all of whom had CD4 counts &lt;100 <span class=\"nowrap\">cells/microL</span> [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/20\" class=\"abstract_t\">20</a>].</p><p/><p class=\"headingAnchor\" id=\"H2025512053\"><span class=\"h2\">Antiretroviral therapy</span></p><p class=\"headingAnchor\" id=\"H1059142102\"><span class=\"h3\">Timing</span></p><p class=\"headingAnchor\" id=\"H131224098\"><span class=\"h4\">Clinical approach</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We agree with the World Health Organization (WHO), which recommends ART in all HIV-infected patients with active TB, regardless of CD4 cell count [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/11\" class=\"abstract_t\">11</a>]. In addition, we agree with the United States Department of Health and Human Services (DHHS) and the American Thoracic Society <span class=\"nowrap\">(ATS)/United</span> States Centers for Disease Control and Prevention <span class=\"nowrap\">(CDC)/Infectious</span> Diseases Society of America (IDSA), which recommend &quot;integrated ART&quot; (eg, within two to eight weeks after initiating anti-TB therapy) rather than &quot;sequential ART&quot; (eg, after completion of antituberculous therapy) for all HIV-infected patients with active TB [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/1,2\" class=\"abstract_t\">1,2</a>]. ART initiation should never be delayed until the completion of TB treatment; this approach has been associated with increased morbidity and mortality.</p><p>TB medications and ART should not be initiated simultaneously. The optimal timing of integrated HIV and TB therapy depends on the patient's immune status [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/1,2,11,21-25\" class=\"abstract_t\">1,2,11,21-25</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with pulmonary TB and CD4 cell count &lt;50 <span class=\"nowrap\">cells/microL,</span> ART should be initiated as soon as possible but within two weeks after initiation of TB treatment. This approach reduces the combined risk of an AIDS-defining illness and death, despite an increased risk for TB immune reconstitution inflammatory syndrome (IRIS).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with pulmonary TB and CD4 count &ge;50 <span class=\"nowrap\">cells/microL,</span> ART should be initiated within eight weeks after initiation of TB treatment. In the absence of severe disease, early ART is not associated with a decreased risk of AIDS or death, and later initiation of ART (eg, eight weeks) is associated with a lower risk of IRIS regardless of baseline CD4 cell count.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with TB involving the central nervous system (CNS), ART should be delayed for the first eight weeks of antituberculous therapy, regardless of CD4 count. Issues related to CNS tuberculosis are discussed separately. (See <a href=\"topic.htm?path=central-nervous-system-tuberculosis\" class=\"medical medical_review\">&quot;Central nervous system tuberculosis&quot;</a>.)</p><p/><p>Other clinical considerations (apart from immune status) may influence clinical decisions regarding the timing of ART. Later initiation of ART (eg, eight weeks) may be preferred based on the patient's tolerance of TB medications and ability to swallow multiple pills, while earlier initiation of ART (eg, within two weeks) may be considered in a patient with malnutrition or wasting, regardless of CD4 cell count.</p><p>Most studies on the timing of ART have been conducted in patients with smear-positive tuberculosis; this subset represents &le;50 percent of all patients treated for pulmonary tuberculosis in developing countries; it is not known if outcomes are comparable in patients with smear-negative disease [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/26\" class=\"abstract_t\">26</a>].</p><p>HIV drug-resistance testing should be performed in preparation for ART selection. The choice of ART depends on patient comorbidities, HIV drug-resistance patterns, and cost considerations. (See <a href=\"topic.htm?path=selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient\" class=\"medical medical_review\">&quot;Selecting antiretroviral regimens for the treatment-na&iuml;ve HIV-infected patient&quot;</a> and <a href=\"topic.htm?path=overview-of-hiv-drug-resistance-testing-assays\" class=\"medical medical_review\">&quot;Overview of HIV drug resistance testing assays&quot;</a>.)</p><p>Management of IRIS is discussed separately. (See <a href=\"topic.htm?path=immune-reconstitution-inflammatory-syndrome\" class=\"medical medical_review\">&quot;Immune reconstitution inflammatory syndrome&quot;</a> and <a href=\"topic.htm?path=treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy\" class=\"medical medical_review\">&quot;Treatment of pulmonary tuberculosis in HIV-infected adults: Follow-up after initiation of therapy&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3523796940\"><span class=\"h4\">Evidence from clinical trials</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The recommendation for integrated ART (initiation of ART during TB therapy) over sequential ART (initiating ART after completion of TB therapy) is based on findings from a randomized trial including 642 patients with sputum smear-positive TB in South Africa (the SAPiT trial), in which patients were treated with integrated ART (initiated less than 4 weeks or within 8 to 12 weeks after initiation of TB therapy) or sequential ART (administered after completion of TB treatment [ie, at six months]) [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/27\" class=\"abstract_t\">27</a>]. All-cause mortality was 56 percent lower in the two integrated treatment arms compared with the sequential treatment arm (hazard ratio 0.44, 95% CI 0.25-0.79). A subsequent analysis of the trial data noted the incidence of IRIS assessed in the treatment groups was 19.5, 7.5, and 8.1 per 100 person-years, respectively. Among those with CD4 counts &lt;50 <span class=\"nowrap\">cells/microL,</span> the incidence of IRIS was 45.5, 9.7, and 19.7 per 100 person-years, respectively [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/28\" class=\"abstract_t\">28</a>].</p><p>Additional studies have evaluated the optimal timing of integrated ART relative to antituberculous therapy [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/29\" class=\"abstract_t\">29</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the SAPiT trial of patients with CD4 count &lt;500 <span class=\"nowrap\">cells/microL,</span> the risk of AIDS or death did not differ between the two integrated therapy arms [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/21\" class=\"abstract_t\">21</a>]. However, among those with a CD4 count &lt;50 <span class=\"nowrap\">cells/microL,</span> the risk of AIDS or death was lower among those who initiated ART within 4 weeks of antituberculous therapy compared with 8 to 12 weeks. Among the patients with a CD4 count &ge;50 <span class=\"nowrap\">cells/microL,</span> rates of IRIS were 16 percent in the 4-week group and 7 percent in the 8- to 12-week group.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A controlled trial in Cambodia (CAMELIA) assessed whether initiation of ART within two weeks of anti-TB therapy offered greater survival benefit than starting ART after eight weeks among 661 HIV-infected patients with a CD4 cell count &lt;200 <span class=\"nowrap\">cells/microL</span> (median CD4 25 <span class=\"nowrap\">cells/microL)</span> [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/22\" class=\"abstract_t\">22</a>]. Mortality was significantly lower among patients assigned to the &quot;early&quot; ART arm compared with the &quot;late&quot; ART arm (18 versus 27 percent), although rates of IRIS were two times higher.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the AIDS Clinical Trials Group (ACTG) 5221 trial (STRIDE), 809 patients with confirmed or suspected tuberculosis and CD4 counts &lt;250 were randomly assigned to &quot;immediate&quot; ART (ie, less than 2 weeks) or &quot;early&quot; ART (ie, 8 to 12 weeks) after the initiation of TB therapy [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/23\" class=\"abstract_t\">23</a>]. Immediate ART reduced the risk of AIDS and mortality among patients with a CD4 count &lt;50 <span class=\"nowrap\">cells/microL,</span> although IRIS occurred more commonly among patients assigned to this arm than to &quot;early&quot; ART (11 versus 5 percent). No difference in AIDS or mortality rates were seen among those patients with a CD4 count &gt;50 <span class=\"nowrap\">cells/microL</span>.</p><p/><p>In general, rates of HIV viral suppression did not differ by ART strategy [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/22,23\" class=\"abstract_t\">22,23</a>], although there were more changes in antiretroviral medications among patients in the early ART arm [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/21\" class=\"abstract_t\">21</a>]. The risk of IRIS and drug toxicity was higher among patients who initiated ART at earlier time points than later within the course of TB treatment [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/21-23,27\" class=\"abstract_t\">21-23,27</a>]. There were no deaths related specifically to IRIS; steroids were required for the management of complications in some patients [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/27\" class=\"abstract_t\">27</a>].</p><p>In another study including 478 Ethiopian patients with TB and HIV with CD4 count &lt;200 <span class=\"nowrap\">cells/microL</span> (median CD4 count 73 <span class=\"nowrap\">cells/microL)</span> randomized to start efavirenz-based antiretroviral therapy one week, four weeks, or eight weeks after the start of antituberculous therapy, mortality rates at 48 weeks were 25, 18, and 15 per 100 person-years, respectively. The mortality rates were similar among individuals with &lt;50 CD4 <span class=\"nowrap\">cells/mcL</span> [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/30\" class=\"abstract_t\">30</a>].</p><p>A separate study demonstrated no benefit of integrated ART in patients with pulmonary TB and higher CD4 cell counts. In a randomized trial performed in several African countries including 1675 patients with smear-positive, culture-confirmed TB and CD4 cell counts &ge;220 <span class=\"nowrap\">cells/microL</span> who were randomly assigned to start ART after two weeks of TB therapy or to start placebo (followed by a switch to ART after completion of six months of TB therapy), there was no significant difference between the two groups in the combined endpoint of TB treatment failure, TB recurrence, or death within 12 months of starting TB treatment [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/25\" class=\"abstract_t\">25</a>].</p><p class=\"headingAnchor\" id=\"H2747141999\"><span class=\"h3\">Regimen selection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The selection of the ART regimen depends on multiple factors including patient comorbidities, drug resistance, drug interactions with antituberculous therapy, and cost. When feasible, it is preferable to select an ART regimen that is compatible with a rifampin-based antituberculous regimen. (See <a href=\"#H401496881\" class=\"local\">'TB regimens based on the rifamycin component'</a> below.)</p><p>The selection of ART regimens and the issues related to the various antiretroviral drug classes for the treatment of HIV are discussed in detail separately. (See <a href=\"topic.htm?path=selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient\" class=\"medical medical_review\">&quot;Selecting antiretroviral regimens for the treatment-na&iuml;ve HIV-infected patient&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1348515847\"><span class=\"h1\">HIV DIAGNOSED PRIOR TO TB</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with human immunodeficiency virus (HIV) infection who are already on antiretroviral therapy (ART) should continue ART and initiate antituberculous therapy as soon as possible.</p><p class=\"headingAnchor\" id=\"H4105042125\"><span class=\"h2\">Antiretroviral therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>If viral suppression has been attained and the current ART regimen is well-tolerated, the ART regimen should be continued if possible and the antituberculous regimen adjusted accordingly.</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Antituberculous therapy</span></p><p class=\"headingAnchor\" id=\"H3230097013\"><span class=\"h3\">Regimen selection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In general, the approach to selection of antituberculous therapy in HIV-infected adults is the same as for adults without HIV infection [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/1\" class=\"abstract_t\">1</a>]. Pending drug-resistance testing results, an empiric four-drug regimen should be initiated (<a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a>, a rifamycin [eg, <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> or <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a>], <a href=\"topic.htm?path=pyrazinamide-drug-information\" class=\"drug drug_general\">pyrazinamide</a>, and <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a>) with pyridoxine and daily therapy using directly observed therapy (DOT) (<a href=\"image.htm?imageKey=ID%2F58653\" class=\"graphic graphic_table graphicRef58653 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/2,11\" class=\"abstract_t\">2,11</a>]. (See <a href=\"topic.htm?path=treatment-of-drug-susceptible-pulmonary-tuberculosis-in-hiv-uninfected-adults\" class=\"medical medical_review\">&quot;Treatment of drug-susceptible pulmonary tuberculosis in HIV-uninfected adults&quot;</a>.)</p><p>A rifamycin is a key component of TB treatment; regimens that do not include a rifamycin are less effective [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/31\" class=\"abstract_t\">31</a>]. <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">Rifampin</a> and <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a> are considered comparable in terms of activity against <em>Mycobacterium tuberculosis</em>. In HIV-infected patients, the choice of agent is governed by HIV drug interactions and cost considerations. (See <a href=\"#H12\" class=\"local\">'Rifampin-based regimens'</a> below and <a href=\"#H1573156343\" class=\"local\">'Rifabutin-based regimens'</a> below.)</p><p>There are a number of interactions between <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> and antiretroviral agents. The main consideration in choice of antituberculous therapy consists of selecting a rifamycin that will minimize the likelihood of significant drug interactions with ART and interference with HIV viral suppression:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients whose ART regimen contains a protease inhibitor (PI), <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a> is the preferred rifamycin. <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">Rifampin</a> should not be given.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients whose ART regimen contains a nonnucleoside reverse-transcriptase inhibitor (NNRTI), the rifamycin used depends on the NNRTI:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For patients receiving <a href=\"topic.htm?path=efavirenz-drug-information\" class=\"drug drug_general\">efavirenz</a>, <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> is the preferred rifamycin; <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a> could also be given.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For patients receiving <a href=\"topic.htm?path=nevirapine-drug-information\" class=\"drug drug_general\">nevirapine</a>, <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a> is the preferred rifamycin.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For patients receiving <a href=\"topic.htm?path=rilpivirine-drug-information\" class=\"drug drug_general\">rilpivirine</a> or <a href=\"topic.htm?path=etravirine-drug-information\" class=\"drug drug_general\">etravirine</a>, <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a> should be administered (<a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> should not be given).</p><p/><p class=\"bulletIndent1\">In general, <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a> has fewer drug interactions than <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a>; however, rifampin is more cost-effective than rifabutin in resource-limited settings. (See <a href=\"#H401496881\" class=\"local\">'TB regimens based on the rifamycin component'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients whose ART regimen contains an integrase strand transfer inhibitor (INSTI), the dose of the INSTI may need to be increased if <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> is given or the ART regimen may need to be changed. <a href=\"topic.htm?path=raltegravir-drug-information\" class=\"drug drug_general\">Raltegravir</a> and <a href=\"topic.htm?path=dolutegravir-drug-information\" class=\"drug drug_general\">dolutegravir</a> may be given with <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a>; raltegravir can also be given with rifampin.</p><p/><p class=\"headingAnchor\" id=\"H3978628283\"><span class=\"h3\">Dosing interval</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Issues related to dosing interval are discussed above. (See <a href=\"#H1427539624\" class=\"local\">'Dosing interval'</a> above.)</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">DRUG INTERACTIONS</span></p><p class=\"headingAnchor\" id=\"H1128744305\"><span class=\"h2\">General principles</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Careful review for drug interactions is essential when considering antituberculous therapy in patients taking antiretroviral therapy (ART). Such interactions can interfere with efficacy of therapy for either HIV or TB infection. A useful tool for HIV drug interactions may be found <a href=\"http://www.hiv-druginteractions.org/&amp;token=+mtJJc/IdrUJXLZzfEZwULieQwurKUEReWusjoliXFtmKMX3KFV93SHf7fIYLgDI&amp;TOPIC_ID=8013\" target=\"_blank\" class=\"external\">online</a>.</p><p class=\"headingAnchor\" id=\"H401496881\"><span class=\"h2\">TB regimens based on the rifamycin component</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Rifamycins induce hepatic CYP3A4 enzymes that can accelerate metabolism of protease inhibitors and some nonnucleoside reverse transcriptase inhibitors (NNRTIs) [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/31,32\" class=\"abstract_t\">31,32</a>]. <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">Rifampin</a> is a much more potent inducer than <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a>. Conversely, serum concentrations of rifabutin may be decreased by the concomitant administration of certain antiretroviral drugs (eg, <a href=\"topic.htm?path=efavirenz-drug-information\" class=\"drug drug_general\">efavirenz</a>).</p><p>Despite the complexity of managing drug interactions, rifamycins are integral to the success of TB therapy and should not be substituted with other antituberculosis medications based on concerns regarding drug interactions alone [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/2,31\" class=\"abstract_t\">2,31</a>]. The following sections address selection of antiretroviral medications with either a rifampin- or a rifabutin-based TB regimen.</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h3\">Rifampin-based regimens</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A limited number of antiretroviral medications within a limited number of drug classes can be coadministered with rifampin-based TB treatment, due to drug interactions that adversely affect HIV treatment efficacy.</p><p>The ART regimen most commonly administered concomitantly with a rifampin-based TB regimen consists of the NNRTI <a href=\"topic.htm?path=efavirenz-drug-information\" class=\"drug drug_general\">efavirenz</a>, together with two nucleoside analogs [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/31,33\" class=\"abstract_t\">31,33</a>]. Regimens that include the integrase strand transfer inhibitors (INSTI) <a href=\"topic.htm?path=raltegravir-drug-information\" class=\"drug drug_general\">raltegravir</a> or <a href=\"topic.htm?path=dolutegravir-drug-information\" class=\"drug drug_general\">dolutegravir</a> may also be administered with <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/2\" class=\"abstract_t\">2</a>].</p><p>Drug interaction information related to specific ART drug classes and rifampin-based TB therapy is discussed below. (See <a href=\"#H2563056355\" class=\"local\">'Rifampin-based regimens with ART'</a> below.)</p><p class=\"headingAnchor\" id=\"H1573156343\"><span class=\"h3\">Rifabutin-based regimens</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">Rifabutin</a> is associated with fewer drug-drug interactions with antiretroviral agents than <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a>. Rifabutin is as effective as rifampin for treatment of tuberculosis when used in combination therapy. However, rifabutin is more expensive than rifampin, and distribution is limited in resource-limited settings. The adverse effects of rifampin and rifabutin are comparable.</p><p><a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">Rifabutin</a> may be coadministered with nucleoside analogs (except <a href=\"topic.htm?path=tenofovir-alafenamide-drug-information\" class=\"drug drug_general\">tenofovir alafenamide</a> [TAF]), protease inhibitors, nonnucleoside reverse transcriptase inhibitors, and integrase strand transfer inhibitors (except <a href=\"topic.htm?path=elvitegravir-drug-information\" class=\"drug drug_general\">elvitegravir</a>). The standard dose of rifabutin is 300 mg daily; however, when dosed with antiretroviral therapy, rifabutin often requires dose adjustments depending on the coadministered drug. A useful tool for HIV drug interactions may be found <a href=\"http://www.hiv-druginteractions.org/&amp;token=+mtJJc/IdrUJXLZzfEZwULieQwurKUEReWusjoliXFtmKMX3KFV93SHf7fIYLgDI&amp;TOPIC_ID=8013\" target=\"_blank\" class=\"external\">online</a>.</p><p><a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">Rifabutin</a> is a substrate for CYP3A4. Thus, its serum concentration is affected by the degree to which CYP3A4 is inhibited or induced by the coadministered drug (<a href=\"image.htm?imageKey=CARD%2F76992\" class=\"graphic graphic_table graphicRef76992 \">table 2</a>). </p><p>Drug interaction information related to specific ART drug classes and rifabutin-based TB therapy is discussed below. (See <a href=\"#H4243351621\" class=\"local\">'Rifabutin-based regimens with ART'</a> below.)</p><p class=\"headingAnchor\" id=\"H1406331775\"><span class=\"h2\">Interactions between ART classes and rifamycins</span></p><p class=\"headingAnchor\" id=\"H2563056355\"><span class=\"h3\">Rifampin-based regimens with ART</span></p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h4\">Nucleoside analogs</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Nucleoside analogs may be coadministered with <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a>; a notable exception is <a href=\"topic.htm?path=tenofovir-alafenamide-drug-information\" class=\"drug drug_general\">tenofovir alafenamide</a>. Rifampin decreases drug levels of TAF, so TAF should not be given with rifamycins [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/2\" class=\"abstract_t\">2</a>]. Rifamycins are potent inducers of P-glycoprotein, and TAF is a P-glycoprotein substrate.</p><p>The nucleotide analog <a href=\"topic.htm?path=tenofovir-disoproxil-fumarate-drug-information\" class=\"drug drug_general\">tenofovir disoproxil fumarate</a> (TDF) does not have substantial interactions with <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a>, so TDF and rifampin may be coadministered.</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h4\">Nonnucleoside reverse transcriptase inhibitors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients receiving NNRTI-based ART with a rifampin-based TB regimen, the preferred NNRTI is <a href=\"topic.htm?path=efavirenz-drug-information\" class=\"drug drug_general\">efavirenz</a>. Viral suppression rates are more favorable with efavirenz-based than nevirapine-based ART; this is because use of <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> reduces <a href=\"topic.htm?path=nevirapine-drug-information\" class=\"drug drug_general\">nevirapine</a> concentrations to a greater degree than efavirenz concentrations [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/31,33-37\" class=\"abstract_t\">31,33-37</a>]. In addition, several trials of ART in treatment-na&iuml;ve patients have shown that nevirapine is associated with higher rates of hepatotoxicity than efavirenz [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/38\" class=\"abstract_t\">38</a>]; this is important since antituberculous agents can also cause drug-induced liver injury. (See <a href=\"topic.htm?path=treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy\" class=\"medical medical_review\">&quot;Treatment of pulmonary tuberculosis in HIV-infected adults: Follow-up after initiation of therapy&quot;</a>.)</p><p>The appropriate dose of <a href=\"topic.htm?path=efavirenz-drug-information\" class=\"drug drug_general\">efavirenz</a> with <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> is somewhat controversial [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/31,33\" class=\"abstract_t\">31,33</a>]. We are in agreement with the United States Department of Health and Human Services (DHHS) and United States Centers for Disease Control and Prevention (CDC) guidelines, which favor the standard efavirenz dose (600 mg daily) among individuals treated with rifampin [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/2\" class=\"abstract_t\">2</a>]. Issues related to use of efavirenz in pregnancy are discussed separately. (See <a href=\"topic.htm?path=safety-and-dosing-of-antiretroviral-medications-in-pregnancy\" class=\"medical medical_review\">&quot;Safety and dosing of antiretroviral medications in pregnancy&quot;</a>.)</p><p><a href=\"topic.htm?path=efavirenz-drug-information\" class=\"drug drug_general\">Efavirenz</a> levels are generally higher in patients from Southern Africa, West Africa, and India due to varying pharmacogenetics of efavirenz among different ethnic and racial groups [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/39-41\" class=\"abstract_t\">39-41</a>].</p><p>Initiation of <a href=\"topic.htm?path=nevirapine-drug-information\" class=\"drug drug_general\">nevirapine</a> should be avoided in patients who are already on antituberculous therapy, due to risk of virologic failure. However, virologically suppressed patients on nevirapine-containing ART who develop TB may continue the same ART regimen [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/33\" class=\"abstract_t\">33</a>]. This was illustrated in a cohort study including more than 2000 patients in South Africa; virologic outcomes were comparable when starting efavirenz-based ART (versus without concurrent tuberculosis) or when tuberculosis developed while taking established nevirapine- or efavirenz-based therapies.</p><p><a href=\"topic.htm?path=nevirapine-drug-information\" class=\"drug drug_general\">Nevirapine</a> may be an acceptable alternative for patients unable to tolerate <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/36\" class=\"abstract_t\">36</a>]. If nevirapine is administered to patients already on rifampin, dosing consists of 200 mg twice daily (with no lead-in phase) [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/2\" class=\"abstract_t\">2</a>]. Increasing the dose of nevirapine is not beneficial. In one trial comparing standard dosing of nevirapine (200 mg twice daily) with a higher dose (300 mg twice daily), increased rates of hypersensitivity were observed among those randomized to the higher dose [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/42\" class=\"abstract_t\">42</a>].</p><p>The NNRTIs <a href=\"topic.htm?path=rilpivirine-drug-information\" class=\"drug drug_general\">rilpivirine</a> and <a href=\"topic.htm?path=etravirine-drug-information\" class=\"drug drug_general\">etravirine</a> should not be used with <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/2,31\" class=\"abstract_t\">2,31</a>]. Rifampin substantially decreases concentrations of rilpivirine and is expected to have similar effects with etravirine.</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h4\">Protease inhibitors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Protease inhibitor (PI)-based ART should not be administered with <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/2\" class=\"abstract_t\">2</a>]. <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">Rifabutin</a>, rather than rifampin, should be used when protease inhibitors are used for HIV therapy. (See <a href=\"#H4243351621\" class=\"local\">'Rifabutin-based regimens with ART'</a> below.)</p><p>In HIV-infected patients initiating ART, PIs are usually dosed with the pharmacokinetic enhancer <a href=\"topic.htm?path=ritonavir-drug-information\" class=\"drug drug_general\">ritonavir</a>, which boosts serum drug levels. Administration of <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> with boosted PIs is associated with reduction of PI levels by as much as 95 percent [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/43,44\" class=\"abstract_t\">43,44</a>].</p><p>Some studies have evaluated dose increments of a particular PI (eg, lopinavir or <a href=\"topic.htm?path=atazanavir-drug-information\" class=\"drug drug_general\">atazanavir</a>) to determine if serum concentrations can be maintained with <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a>. However, this approach has been associated with significant adverse events including gastrointestinal intolerance and hepatotoxicity [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/43-46\" class=\"abstract_t\">43-46</a>].</p><p class=\"headingAnchor\" id=\"H20\"><span class=\"h4\">Integrase inhibitors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">Rifampin</a> and <a href=\"topic.htm?path=raltegravir-drug-information\" class=\"drug drug_general\">raltegravir</a> may be coadministered with caution; viral load monitoring is required. We favor doubling the dose of raltegravir when coadministered with rifampin [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/47\" class=\"abstract_t\">47</a>]. Rifampin decreases serum levels of raltegravir by 40 to 61 percent [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/48\" class=\"abstract_t\">48</a>]. Standard raltegravir dosing (400 mg twice daily) may be sufficient [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/49,50\" class=\"abstract_t\">49,50</a>]; doubling the dose of raltegravir (to 800 mg twice daily) may improve drug levels [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/47\" class=\"abstract_t\">47</a>].</p><p>We favor doubling the dose of <a href=\"topic.htm?path=dolutegravir-drug-information\" class=\"drug drug_general\">dolutegravir</a> when coadministered with <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/2\" class=\"abstract_t\">2</a>]. A small study suggested that dolutegravir levels (with twice-daily dosing) are not significantly affected by rifampin [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/51\" class=\"abstract_t\">51</a>], but there is little clinical experience with these drugs given in combination. If integrase inhibitor resistance is suspected or confirmed, use of <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a> may be preferable to rifampin.</p><p><a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">Rifampin</a> should not be administered with the fixed-dose combination of <a href=\"topic.htm?path=elvitegravir-drug-information\" class=\"drug drug_general\">elvitegravir</a>, <a href=\"topic.htm?path=cobicistat-drug-information\" class=\"drug drug_general\">cobicistat</a>, tenofovir, and <a href=\"topic.htm?path=emtricitabine-drug-information\" class=\"drug drug_general\">emtricitabine</a>, as rifampin is expected to decrease concentrations of both elvitegravir and cobicistat [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/31\" class=\"abstract_t\">31</a>].</p><p class=\"headingAnchor\" id=\"H21\"><span class=\"h4\">Other ART classes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=maraviroc-drug-information\" class=\"drug drug_general\">Maraviroc</a> (a CCR5 receptor antagonist) should not be coadministered with <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/2\" class=\"abstract_t\">2</a>]. Rifampin decreases serum levels of maraviroc by 78 percent; there is no published experience regarding efficacy or toxicity of this combination.</p><p><a href=\"topic.htm?path=enfuvirtide-drug-information\" class=\"drug drug_general\">Enfuvirtide</a> (a fusion inhibitor) may be coadministered with <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a>; there are no interactions between these agents.</p><p class=\"headingAnchor\" id=\"H4243351621\"><span class=\"h3\">Rifabutin-based regimens with ART</span></p><p class=\"headingAnchor\" id=\"H24\"><span class=\"h4\">Nucleoside analogs</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Nucleoside analogs may be coadministered with <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a>; a notable exception is <a href=\"topic.htm?path=tenofovir-alafenamide-drug-information\" class=\"drug drug_general\">tenofovir alafenamide</a>. Rifabutin decreases drug levels of TAF, so TAF should not be given with rifamycins [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/2\" class=\"abstract_t\">2</a>]. Rifamycins are potent inducers of P-glycoprotein, and TAF is a P-glycoprotein substrate.</p><p>The nucleotide analog <a href=\"topic.htm?path=tenofovir-disoproxil-fumarate-drug-information\" class=\"drug drug_general\">tenofovir disoproxil fumarate</a> does not have substantial interactions with <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a>, so TDF and rifabutin may be coadministered.</p><p class=\"headingAnchor\" id=\"H25\"><span class=\"h4\">Nonnucleoside reverse transcriptase inhibitors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=efavirenz-drug-information\" class=\"drug drug_general\">Efavirenz</a> can reduce serum concentrations of <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a>. Therefore, if efavirenz is administered, the dose of rifabutin should be increased from the standard dose of 300 mg to 450 to 600 <span class=\"nowrap\">mg/day</span> [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/2,31,52\" class=\"abstract_t\">2,31,52</a>]. A useful tool for HIV drug interactions may be found <a href=\"http://www.hiv-druginteractions.org/&amp;token=+mtJJc/IdrUJXLZzfEZwULieQwurKUEReWusjoliXFtmKMX3KFV93SHf7fIYLgDI&amp;TOPIC_ID=8013\" target=\"_blank\" class=\"external\">online</a>.</p><p>There are no significant drug interactions between <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a> and <a href=\"topic.htm?path=nevirapine-drug-information\" class=\"drug drug_general\">nevirapine</a>.</p><p><a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">Rifabutin</a> can be given with <a href=\"topic.htm?path=etravirine-drug-information\" class=\"drug drug_general\">etravirine</a> or <a href=\"topic.htm?path=rilpivirine-drug-information\" class=\"drug drug_general\">rilpivirine</a>; dose adjustments may be necessary [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/2\" class=\"abstract_t\">2</a>].</p><p class=\"headingAnchor\" id=\"H26\"><span class=\"h4\">Protease inhibitors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Protease inhibitors can be coadministered with <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a> without significantly compromising the serum drug concentrations, with or without the coadministration of <a href=\"topic.htm?path=ritonavir-drug-information\" class=\"drug drug_general\">ritonavir</a> or <a href=\"topic.htm?path=cobicistat-drug-information\" class=\"drug drug_general\">cobicistat</a> for pharmacologic boosting [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/53\" class=\"abstract_t\">53</a>]. The dose of rifabutin should be decreased from 300 mg daily to 150 mg daily (or 300 mg three times per week). A useful tool for HIV drug interactions may be found <a href=\"http://www.hiv-druginteractions.org/&amp;token=+mtJJc/IdrUJXLZzfEZwULieQwurKUEReWusjoliXFtmKMX3KFV93SHf7fIYLgDI&amp;TOPIC_ID=8013\" target=\"_blank\" class=\"external\">online</a>.</p><p>The <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a> dose previously recommended for coadministration with ritonavir-boosted PIs (150 mg three times weekly) has been associated with insufficient rifabutin levels [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/54\" class=\"abstract_t\">54</a>]. In addition, there have been reports of acquired rifamycin resistance among individuals receiving this dose [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/15\" class=\"abstract_t\">15</a>].</p><p>There are no published data on coadministration of <a href=\"topic.htm?path=darunavir-drug-information\" class=\"drug drug_general\">darunavir</a> and <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a>.</p><p class=\"headingAnchor\" id=\"H27\"><span class=\"h4\">Integrase inhibitors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">Rifabutin</a> does not appear to substantially affect <a href=\"topic.htm?path=raltegravir-drug-information\" class=\"drug drug_general\">raltegravir</a> or <a href=\"topic.htm?path=dolutegravir-drug-information\" class=\"drug drug_general\">dolutegravir</a> concentrations (based on limited in vitro data) [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/51,55\" class=\"abstract_t\">51,55</a>]. If coadministered with rifabutin, the dose of raltegravir or dolutegravir does not need to be increased [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/2,31\" class=\"abstract_t\">2,31</a>].</p><p><a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">Rifabutin</a> should not be used with the fixed-dose combination of <a href=\"topic.htm?path=elvitegravir-drug-information\" class=\"drug drug_general\">elvitegravir</a>, <a href=\"topic.htm?path=cobicistat-drug-information\" class=\"drug drug_general\">cobicistat</a>, tenofovir, and <a href=\"topic.htm?path=emtricitabine-drug-information\" class=\"drug drug_general\">emtricitabine</a>, given decreased elvitegravir levels.</p><p class=\"headingAnchor\" id=\"H2647385662\"><span class=\"h4\">Other ART classes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are no published data on the combined use of <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a> and <a href=\"topic.htm?path=maraviroc-drug-information\" class=\"drug drug_general\">maraviroc</a>. Dosing recommendations vary according to the concomitant medications [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/2\" class=\"abstract_t\">2</a>]. A useful tool for HIV drug interactions may be found <a href=\"http://www.hiv-druginteractions.org/&amp;token=+mtJJc/IdrUJXLZzfEZwULieQwurKUEReWusjoliXFtmKMX3KFV93SHf7fIYLgDI&amp;TOPIC_ID=8013\" target=\"_blank\" class=\"external\">online</a>.</p><p>There are no drug interactions between the fusion inhibitor <a href=\"topic.htm?path=enfuvirtide-drug-information\" class=\"drug drug_general\">enfuvirtide</a> and <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a>.</p><p class=\"headingAnchor\" id=\"H1234662340\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-diagnosis-and-treatment-of-tuberculosis\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Diagnosis and treatment of tuberculosis&quot;</a> and <a href=\"topic.htm?path=society-guideline-links-opportunistic-infections-in-hiv-infected-adults-and-adolescents\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Opportunistic infections in HIV-infected adults and adolescents&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H38\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Initiation of therapy for treatment of drug-susceptible pulmonary tuberculosis (TB) in HIV-infected adults must address potential drug interactions and adverse drug reactions. In addition, the clinical approach depends upon which condition is diagnosed first. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with an established diagnosis of TB disease warrant prompt initiation of antituberculous therapy. An empiric four-drug regimen should be initiated (<a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a>, <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a>, <a href=\"topic.htm?path=pyrazinamide-drug-information\" class=\"drug drug_general\">pyrazinamide</a>, and <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a>) with pyridoxine and daily therapy using directly observed therapy (DOT) until drug susceptibility results are available (<a href=\"image.htm?imageKey=ID%2F58653\" class=\"graphic graphic_table graphicRef58653 \">table 1</a>). Depending on the antiretroviral therapy (ART) regimen chosen, adjustment of the antituberculous regimen may be required. (See <a href=\"#H319082495\" class=\"local\">'TB diagnosed prior to HIV'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We recommend that all HIV-infected patients with TB be treated with ART (<a href=\"grade.htm?i=1\" class=\"grade\">Grade 1A</a>). The optimal timing depends on the patient's immune status (see <a href=\"#H1059142102\" class=\"local\">'Timing'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For HIV-infected patients with pulmonary TB and CD4 cell count &lt;50 <span class=\"nowrap\">cells/microL,</span> we recommend initiation of ART within two weeks after starting TB treatment (<a href=\"grade.htm?i=1\" class=\"grade\">Grade 1A</a>).</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For HIV-infected patients with pulmonary TB and CD4 count &ge;50 <span class=\"nowrap\">cells/microL,</span> we recommend initiation of ART within eight weeks after starting TB treatment (<a href=\"grade.htm?i=1\" class=\"grade\">Grade 1A</a>).</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For HIV-infected patients with TB involving the central nervous system (CNS), ART should be delayed for the first eight weeks of antituberculous therapy, regardless of CD4 count. Issues related to CNS tuberculosis are discussed separately. (See <a href=\"topic.htm?path=central-nervous-system-tuberculosis\" class=\"medical medical_review\">&quot;Central nervous system tuberculosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with HIV infection who are already on ART should continue the ART regimen and initiate antituberculous therapy as soon as possible. If viral suppression has been attained and the current ART regimen is well-tolerated, the ART regimen should be continued and the antituberculous regimen adjusted accordingly. (See <a href=\"#H1348515847\" class=\"local\">'HIV diagnosed prior to TB'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pending drug susceptibility results, an empiric four-drug regimen should be initiated (<a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a>, a rifamycin [eg, <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> or <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a>], <a href=\"topic.htm?path=pyrazinamide-drug-information\" class=\"drug drug_general\">pyrazinamide</a>, and <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a>) with pyridoxine and daily therapy using DOT (<a href=\"image.htm?imageKey=ID%2F58653\" class=\"graphic graphic_table graphicRef58653 \">table 1</a>). The main consideration consists of selecting a rifamycin that will minimize the likelihood of drug interactions with ART and interference with HIV viral suppression. A useful tool for HIV drug interactions may be found <a href=\"http://www.hiv-druginteractions.org/&amp;token=+mtJJc/IdrUJXLZzfEZwULieQwurKUEReWusjoliXFtmKMX3KFV93SHf7fIYLgDI&amp;TOPIC_ID=8013\" target=\"_blank\" class=\"external\">online</a>. (See <a href=\"#H3\" class=\"local\">'Antituberculous therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>When feasible, it is preferable to select an ART regimen that is compatible with a rifampin-based antituberculous regimen. However, there are a number of drug interactions between <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> and antiretroviral agents. <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">Rifabutin</a> is as effective as rifampin for treatment of TB when used in combination therapy and is associated with fewer drug interactions with antiretroviral agents than rifampin. However, rifabutin is more expensive than rifampin, and distribution is limited in resource-limited settings. The adverse effects of rifampin and rifabutin are comparable. (See <a href=\"#H3230097013\" class=\"local\">'Regimen selection'</a> above and <a href=\"#H401496881\" class=\"local\">'TB regimens based on the rifamycin component'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with TB and HIV who are receiving a rifampin-based antituberculous regimen, we suggest an ART regimen consisting of the nonnucleoside reverse transcriptase inhibitor (NNRTI) <a href=\"topic.htm?path=efavirenz-drug-information\" class=\"drug drug_general\">efavirenz</a>, together with two nucleoside analogs (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). (See <a href=\"#H12\" class=\"local\">'Rifampin-based regimens'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with TB and HIV who are receiving a rifabutin-based antituberculous regimen, we suggest either a protease inhibitor, nonnucleoside reverse transcriptase inhibitor, or integrase inhibitor, together with two nucleoside analogs (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). (See <a href=\"#H1573156343\" class=\"local\">'Rifabutin-based regimens'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Issues related to follow-up and duration of therapy are discussed separately. (See <a href=\"topic.htm?path=treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy\" class=\"medical medical_review\">&quot;Treatment of pulmonary tuberculosis in HIV-infected adults: Follow-up after initiation of therapy&quot;</a>.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/1\" class=\"nounderline abstract_t\">Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016; 63:e147.</a></li><li class=\"breakAll\">Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf (Accessed on July 10, 2017).</li><li class=\"breakAll\">Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf.</li><li class=\"breakAll\">World Health Organization. Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update. http://apps.who.int/iris/bitstream/10665/255052/1/9789241550000-eng.pdf?ua=1 (Accessed on June 08, 2017).</li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/5\" class=\"nounderline abstract_t\">Onyebujoh PC, Ribeiro I, Whalen CC. Treatment Options for HIV-Associated Tuberculosis. J Infect Dis 2007; 196 Suppl 1:S35.</a></li><li class=\"breakAll\">Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf (Accessed on January 19, 2016).</li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/7\" class=\"nounderline abstract_t\">Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330:1179.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/8\" class=\"nounderline abstract_t\">Dye C, Watt CJ, Bleed DM, et al. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA 2005; 293:2767.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/9\" class=\"nounderline abstract_t\">Ntshanga SP, Rustomjee R, Mabaso ML. Evaluation of directly observed therapy for tuberculosis in KwaZulu-Natal, South Africa. Trans R Soc Trop Med Hyg 2009; 103:571.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/10\" class=\"nounderline abstract_t\">Anuwatnonthakate A, Limsomboon P, Nateniyom S, et al. Directly observed therapy and improved tuberculosis treatment outcomes in Thailand. PLoS One 2008; 3:e3089.</a></li><li class=\"breakAll\">New: World Health Organization. Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update. http://apps.who.int/iris/bitstream/10665/255052/1/9789241550000-eng.pdf?ua=1 (Accessed June 16, 2017).</li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/12\" class=\"nounderline abstract_t\">Khan FA, Minion J, Pai M, et al. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis 2010; 50:1288.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/13\" class=\"nounderline abstract_t\">Ahmad Khan F, Minion J, Al-Motairi A, et al. An updated systematic review and meta-analysis on the treatment of active tuberculosis in patients with HIV infection. Clin Infect Dis 2012; 55:1154.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/14\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens. MMWR Morb Mortal Wkly Rep 2002; 51:214.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/15\" class=\"nounderline abstract_t\">Jenny-Avital ER, Joseph K. Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy. Clin Infect Dis 2009; 48:1471.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/16\" class=\"nounderline abstract_t\">Vernon A, Burman W, Benator D, et al. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet 1999; 353:1843.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/17\" class=\"nounderline abstract_t\">Swaminathan S, Narendran G, Venkatesan P, et al. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial. Am J Respir Crit Care Med 2010; 181:743.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/18\" class=\"nounderline abstract_t\">Nettles RE, Mazo D, Alwood K, et al. Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. Clin Infect Dis 2004; 38:731.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/19\" class=\"nounderline abstract_t\">Narendran G, Menon PA, Venkatesan P, et al. Acquired rifampicin resistance in thrice-weekly antituberculosis therapy: impact of HIV and antiretroviral therapy. Clin Infect Dis 2014; 59:1798.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/20\" class=\"nounderline abstract_t\">Burman W, Benator D, Vernon A, et al. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med 2006; 173:350.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/21\" class=\"nounderline abstract_t\">Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011; 365:1492.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/22\" class=\"nounderline abstract_t\">Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011; 365:1471.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/23\" class=\"nounderline abstract_t\">Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011; 365:1482.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/24\" class=\"nounderline abstract_t\">Uthman OA, Okwundu C, Gbenga K, et al. Optimal Timing of Antiretroviral Therapy Initiation for HIV-Infected Adults With Newly Diagnosed Pulmonary Tuberculosis: A Systematic Review and Meta-analysis. Ann Intern Med 2015; 163:32.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/25\" class=\"nounderline abstract_t\">Mfinanga SG, Kirenga BJ, Chanda DM, et al. Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial. Lancet Infect Dis 2014; 14:563.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/26\" class=\"nounderline abstract_t\">von Reyn CF. Optimal treatment of Codisease due to HIV and tuberculosis. J Infect Dis 2011; 204:817.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/27\" class=\"nounderline abstract_t\">Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362:697.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/28\" class=\"nounderline abstract_t\">Naidoo K, Yende-Zuma N, Padayatchi N, et al. The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial. Ann Intern Med 2012; 157:313.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/29\" class=\"nounderline abstract_t\">Suthar AB, Lawn SD, del Amo J, et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med 2012; 9:e1001270.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/30\" class=\"nounderline abstract_t\">Amogne W, Aderaye G, Habtewold A, et al. Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts &lt; 200 Cells/&mu;L: TB-HAART Study, a Randomized Clinical Trial. PLoS One 2015; 10:e0122587.</a></li><li class=\"breakAll\">Centers for Disease Control and Prevention. Managing drug interactions in the treatment of HIV-related tuberculosis. 2013. http://www.cdc.gov/tb/publications/guidelines/TB_HIV_Drugs/default.htm (Accessed on April 20, 2015).</li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/32\" class=\"nounderline abstract_t\">Burger DM, Agarwala S, Child M, et al. Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers. Antimicrob Agents Chemother 2006; 50:3336.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/33\" class=\"nounderline abstract_t\">Boulle A, Van Cutsem G, Cohen K, et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 2008; 300:530.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/34\" class=\"nounderline abstract_t\">Maartens G, Decloedt E, Cohen K. Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries. Antivir Ther 2009; 14:1039.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/35\" class=\"nounderline abstract_t\">Manosuthi W, Sungkanuparph S, Tantanathip P, et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. Clin Infect Dis 2009; 48:1752.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/36\" class=\"nounderline abstract_t\">Bonnet M, Bhatt N, Baudin E, et al. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial. Lancet Infect Dis 2013; 13:303.</a></li><li class=\"breakAll\">Swaminathan, S, Padmapriyadarsini, C, and Venkatesan, P, et al. Once-daily nevirapine versus efavirenz in the treatment of HIV-infected patients with TB: a randomized clinical trial. Presented at the 16th Annual Conference on Retroviruses and Opportunistic Infections, Montreal, Canada February 8-11th, 2009; abstract # 35.</li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/38\" class=\"nounderline abstract_t\">Sulkowski MS, Thomas DL, Mehta SH, et al. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002; 35:182.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/39\" class=\"nounderline abstract_t\">St&ouml;hr W, Back D, Dunn D, et al. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir Ther 2008; 13:675.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/40\" class=\"nounderline abstract_t\">Cohen K, Grant A, Dandara C, et al. Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G&gt;T polymorphism on efavirenz concentrations in adults in South Africa. Antivir Ther 2009; 14:687.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/41\" class=\"nounderline abstract_t\">Gross R, Aplenc R, Tenhave T, et al. Slow efavirenz metabolism genotype is common in Botswana. J Acquir Immune Defic Syndr 2008; 49:336.</a></li><li class=\"breakAll\">Avihingsanon A, Manosuthi W, Kantipong P, et al. Pharmacokinetics and 12 weeks efficacy of nevirapine, 400 mg vs. 600 mg per day in HIV-infected patients with active TB receiving rifampicin: a multicenter study. Presented at the 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA.</li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/43\" class=\"nounderline abstract_t\">Acosta EP, Kendall MA, Gerber JG, et al. Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. Antimicrob Agents Chemother 2007; 51:3104.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/44\" class=\"nounderline abstract_t\">Mallolas J, Sarasa M, Nomdedeu M, et al. Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients. HIV Med 2007; 8:131.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/45\" class=\"nounderline abstract_t\">Haas DW, Koletar SL, Laughlin L, et al. Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir. J Acquir Immune Defic Syndr 2009; 50:290.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/46\" class=\"nounderline abstract_t\">L'homme RF, Nijland HM, Gras L, et al. Clinical experience with the combined use of lopinavir/ritonavir and rifampicin. AIDS 2009; 23:863.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/47\" class=\"nounderline abstract_t\">Wenning LA, Hanley WD, Brainard DM, et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother 2009; 53:2852.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/48\" class=\"nounderline abstract_t\">Pham PA, Flexner C. Emerging antiretroviral drug interactions. J Antimicrob Chemother 2011; 66:235.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/49\" class=\"nounderline abstract_t\">Grinsztejn B, De Castro N, Arnold V, et al. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial. Lancet Infect Dis 2014; 14:459.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/50\" class=\"nounderline abstract_t\">Taburet AM, Sauvageon H, Grinsztejn B, et al. Pharmacokinetics of Raltegravir in HIV-Infected Patients on Rifampicin-Based Antitubercular Therapy. Clin Infect Dis 2015; 61:1328.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/51\" class=\"nounderline abstract_t\">Dooley KE, Sayre P, Borland J, et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr 2013; 62:21.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/52\" class=\"nounderline abstract_t\">Weiner M, Benator D, Peloquin CA, et al. Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis. Clin Infect Dis 2005; 41:1343.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/53\" class=\"nounderline abstract_t\">TB/HIV drug interactions. MMWR Morb Mortal Wkly Rep 2004; 53:37.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/54\" class=\"nounderline abstract_t\">Boulanger C, Hollender E, Farrell K, et al. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin Infect Dis 2009; 49:1305.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy/abstract/55\" class=\"nounderline abstract_t\">Brainard DM, Kassahun K, Wenning LA, et al. Lack of a clinically meaningful pharmacokinetic effect of rifabutin on raltegravir: in vitro/in vivo correlation. J Clin Pharmacol 2011; 51:943.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 8013 Version 61.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H38\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">GENERAL PRINCIPLES</a></li><li><a href=\"#H319082495\" id=\"outline-link-H319082495\">TB DIAGNOSED PRIOR TO HIV</a><ul><li><a href=\"#H3100743462\" id=\"outline-link-H3100743462\">Antituberculous therapy</a><ul><li><a href=\"#H563844985\" id=\"outline-link-H563844985\">- Regimen selection</a></li><li><a href=\"#H1427539624\" id=\"outline-link-H1427539624\">- Dosing interval</a></li></ul></li><li><a href=\"#H2025512053\" id=\"outline-link-H2025512053\">Antiretroviral therapy</a><ul><li><a href=\"#H1059142102\" id=\"outline-link-H1059142102\">- Timing</a><ul><li><a href=\"#H131224098\" id=\"outline-link-H131224098\">Clinical approach</a></li><li><a href=\"#H3523796940\" id=\"outline-link-H3523796940\">Evidence from clinical trials</a></li></ul></li><li><a href=\"#H2747141999\" id=\"outline-link-H2747141999\">- Regimen selection</a></li></ul></li></ul></li><li><a href=\"#H1348515847\" id=\"outline-link-H1348515847\">HIV DIAGNOSED PRIOR TO TB</a><ul><li><a href=\"#H4105042125\" id=\"outline-link-H4105042125\">Antiretroviral therapy</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">Antituberculous therapy</a><ul><li><a href=\"#H3230097013\" id=\"outline-link-H3230097013\">- Regimen selection</a></li><li><a href=\"#H3978628283\" id=\"outline-link-H3978628283\">- Dosing interval</a></li></ul></li></ul></li><li><a href=\"#H11\" id=\"outline-link-H11\">DRUG INTERACTIONS</a><ul><li><a href=\"#H1128744305\" id=\"outline-link-H1128744305\">General principles</a></li><li><a href=\"#H401496881\" id=\"outline-link-H401496881\">TB regimens based on the rifamycin component</a><ul><li><a href=\"#H12\" id=\"outline-link-H12\">- Rifampin-based regimens</a></li><li><a href=\"#H1573156343\" id=\"outline-link-H1573156343\">- Rifabutin-based regimens</a></li></ul></li><li><a href=\"#H1406331775\" id=\"outline-link-H1406331775\">Interactions between ART classes and rifamycins</a><ul><li><a href=\"#H2563056355\" id=\"outline-link-H2563056355\">- Rifampin-based regimens with ART</a><ul><li><a href=\"#H13\" id=\"outline-link-H13\">Nucleoside analogs</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">Nonnucleoside reverse transcriptase inhibitors</a></li><li><a href=\"#H19\" id=\"outline-link-H19\">Protease inhibitors</a></li><li><a href=\"#H20\" id=\"outline-link-H20\">Integrase inhibitors</a></li><li><a href=\"#H21\" id=\"outline-link-H21\">Other ART classes</a></li></ul></li><li><a href=\"#H4243351621\" id=\"outline-link-H4243351621\">- Rifabutin-based regimens with ART</a><ul><li><a href=\"#H24\" id=\"outline-link-H24\">Nucleoside analogs</a></li><li><a href=\"#H25\" id=\"outline-link-H25\">Nonnucleoside reverse transcriptase inhibitors</a></li><li><a href=\"#H26\" id=\"outline-link-H26\">Protease inhibitors</a></li><li><a href=\"#H27\" id=\"outline-link-H27\">Integrase inhibitors</a></li><li><a href=\"#H2647385662\" id=\"outline-link-H2647385662\">Other ART classes</a></li></ul></li></ul></li></ul></li><li><a href=\"#H1234662340\" id=\"outline-link-H1234662340\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H38\" id=\"outline-link-H38\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/8013|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ID/58653\" class=\"graphic graphic_table\">- Drug regimens TB in HIV</a></li><li><a href=\"image.htm?imageKey=CARD/76992\" class=\"graphic graphic_table\">- Cytochrome P450 3A4 (CYP3A4) inhibitors and inducers</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=adherence-to-tuberculosis-treatment\" class=\"medical medical_review\">Adherence to tuberculosis treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=central-nervous-system-tuberculosis\" class=\"medical medical_review\">Central nervous system tuberculosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-of-pulmonary-tuberculosis-in-adults\" class=\"medical medical_review\">Diagnosis of pulmonary tuberculosis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=immune-reconstitution-inflammatory-syndrome\" class=\"medical medical_review\">Immune reconstitution inflammatory syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-hiv-drug-resistance-testing-assays\" class=\"medical medical_review\">Overview of HIV drug resistance testing assays</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-antiretroviral-agents-used-to-treat-hiv\" class=\"medical medical_review\">Overview of antiretroviral agents used to treat HIV</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=safety-and-dosing-of-antiretroviral-medications-in-pregnancy\" class=\"medical medical_review\">Safety and dosing of antiretroviral medications in pregnancy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient\" class=\"medical medical_review\">Selecting antiretroviral regimens for the treatment-na&iuml;ve HIV-infected patient</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-diagnosis-and-treatment-of-tuberculosis\" class=\"medical medical_society_guidelines\">Society guideline links: Diagnosis and treatment of tuberculosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-opportunistic-infections-in-hiv-infected-adults-and-adolescents\" class=\"medical medical_society_guidelines\">Society guideline links: Opportunistic infections in HIV-infected adults and adolescents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults\" class=\"medical medical_review\">Treatment of drug-resistant pulmonary tuberculosis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-drug-susceptible-pulmonary-tuberculosis-in-hiv-uninfected-adults\" class=\"medical medical_review\">Treatment of drug-susceptible pulmonary tuberculosis in HIV-uninfected adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy\" class=\"medical medical_review\">Treatment of pulmonary tuberculosis in HIV-infected adults: Follow-up after initiation of therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=tuberculosis-transmission-and-control\" class=\"medical medical_review\">Tuberculosis transmission and control</a></li></ul></div></div>","javascript":null}